KNSA - Kiniksa Pharmaceuticals, Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
18.29
-0.51 (-2.71%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close18.80
Open18.90
Bid0.00 x 900
Ask18.99 x 1000
Day's Range17.78 - 19.07
52 Week Range16.54 - 24.64
Volume97,756
Avg. Volume265,660
Market Cap885.982M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-36.53
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    Kiniksa Pharmaceuticals to Present at the JMP Securities 2018 Life Sciences Conference

    HAMILTON, Bermuda, June 14, 2018-- Kiniksa Pharmaceuticals, Ltd. announced today that it will be presenting at the JMP Securities 2018 Life Sciences Conference on Thursday, June 21 st, 2018 at 10:30 a.m. ...

  • Breaking Down Kiniksa Pharmaceuticals Ltd’s (NASDAQ:KNSA) Ownership Structure
    Simply Wall St.6 days ago

    Breaking Down Kiniksa Pharmaceuticals Ltd’s (NASDAQ:KNSA) Ownership Structure

    In this analysis, my focus will be on developing a perspective on Kiniksa Pharmaceuticals Ltd’s (NASDAQ:KNSA) latest ownership structure, a less discussed, but important factor. A company’s ownership structure isRead More...

  • GlobeNewswire19 days ago

    Kiniksa Pharmaceuticals, Ltd. Announces Closing of Initial Public Offering

    HAMILTON, Bermuda, May 29, 2018-- Kiniksa Pharmaceuticals, Ltd. announced today the closing of its initial public offering of 8,477,777 Class A common shares at a public offering price of $18.00 per share. ...

  • GlobeNewswire24 days ago

    Nasdaq Welcomes Kiniksa Pharmaceuticals, Ltd. (Nasdaq:KNSA) to The Nasdaq Stock Market

    Kiniksa Pharmaceuticals, Ltd. (KNSA), a clinical-stage biopharmaceutical company, visited the Nasdaq MarketSite in Times Square today for its initial public offering (IPO) on The Nasdaq Stock Market. Kiniksa is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from devastating and debilitating diseases with unmet medical need. “As it works to develop life-changing therapies for debilitating diseases, Kiniksa Pharmaceuticals represents the kind of ambitious, forward-thinking growth company that embodies the Nasdaq spirit,” said Nelson Griggs, President, Nasdaq Stock Exchange.

  • GlobeNewswire25 days ago

    Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Initial Public Offering

    HAMILTON, Bermuda, May 23, 2018-- Kiniksa Pharmaceuticals, Ltd. announced today the pricing of its initial public offering of 8,477,777 Class A common shares at a public offering price of $18.00 per share, ...